XRF Scientific (ASX:XRF): What Is Supporting the Company’s Latest Trading Momentum?

Aditi Sarkar

28 October 2026 08:17 PM AEDT

XRF Scientific (ASX:XRF): What Is Supporting the Company’s Latest Trading Momentum?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

September 2026 quarter revenue reached $21.1 million, up 38% year on year.
Quarterly profit before tax rose 30% to $4.4 million, with integration expenses included.
Orbis sales increased 66% to $2.4 million as equipment demand developed.
FY26 revenue rose 8% to $64.4 million, and adjusted profit before tax reached $16.1 million.
The CGA manufacturing transfer to Perth is central to the December quarter outlook.

XRF Scientific Limited (ASX:XRF) manufactures equipment and chemicals used by mining, manufacturing and analytical laboratory customers to prepare and analyse samples. The company operates across consumables, capital equipment and precious metals products, with international sales and support facilities. Its September 2026 trading update recorded increased revenue and profit before tax across a period that included integration spending for a recently acquired business. The update does not establish a cause for the 28 October share-price movement.

Quarterly Revenue and Profit Move Higher

For the three months ended 30 September 2026, ASX:XRF reported unaudited revenue of $21.1 million, compared with $15.3 million in the September 2025 quarter, representing growth of 38%. Profit before tax increased 30% to $4.4 million from $3.4 million. The company stated that these figures included CGA acquisition integration costs rather than excluding them from the reported outcome.

Consumables revenue was $5.6 million, compared with $4.4 million a year earlier. Capital equipment generated $5.9 million versus $5.0 million, while precious metals sales totalled $9.6 million versus $5.9 million. All three segments contributed revenue.

Orbis Products and International Operations

Within capital equipment, Orbis product revenue increased 66% to $2.4 million during the September quarter. The company linked activity to laboratory demand, the gold sector and the introduction of additional instruments. XRF Scientific also reported that its India office was profitable for the quarter, marking progress in a market where it has been expanding its presence.

For ASX:XRF, sales performance in new offices and across specialist product lines is relevant to the company’s geographic expansion. Future contributions depend on orders and delivery. The quarterly figures are unaudited and should be distinguished from full-year statutory results.

FY26 Results Establish the Financial Baseline

The company’s release of 18 August 2026 reported FY26 revenue of $64.4 million, up 8% from $59.5 million in FY25. Adjusted profit before tax rose 10% to $16.1 million from $14.6 million, while statutory profit before tax increased 5% to $15.4 million. Net operating cash inflow was $11.4 million. The board declared a final fully franked dividend of 4.5 cents per share.

Adjusted profit excludes acquisition and international office establishment costs. The annual report recorded FY26 profit after tax of approximately $10.5 million, compared with approximately $10.3 million in FY25. These figures show a more moderate statutory earnings increase than the adjusted profit measure.

CGA Acquisition Adds an Execution Milestone

ASX:XRF announced in April 2026 that it would acquire the combustion gas analysis business of Bruker AXS SE for US$4.0 million upfront, with an additional earn-out of up to US$1.0 million linked to revenue. The acquired business expands the range of laboratory instruments supplied by XRF Scientific. The September trading report said the manufacturing transfer to Perth was progressing, with instrument production expected to commence in December 2026.

Integration involves production and supply execution. Management expects CGA sales and continued Orbis activity to contribute in the December quarter, but these expectations remain forward-looking rather than realised revenue. The timing of manufacturing start-up and conversion of orders into sales will therefore be important operational measures for ASX:XRF.

Key Insights

The September quarter provides a positive operational data point for ASX:XRF, with higher revenue, profit before tax and Orbis sales following the FY26 improvement. The company also faces practical execution considerations in integrating CGA manufacturing and sustaining international demand. Its financial disclosures establish the reported gains, but do not demonstrate that any particular announcement caused the share-price increase on 28 October 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.